All sponsors

Hangzhou Sumgen Biotech Co., Ltd.

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS6
PHASE 3 / 2-31
RECRUITING5
READOUTS ≤12 MONTHS5
Open Hangzhou Sumgen Biotech Co., Ltd. on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
SG301 Injection
NCT06508983
P3RecruitingRelapsed/Refractory Multiple Myeloma3602027-03-31
SG301 Injection
NCT07764627
P2Not yet recruitingAntibody Mediated Rejection102027-03-31
low dose group
NCT07710248
P2RecruitingPrimary Immune Thrombocytopenia602027-05-17
SG301 SC Injection
NCT07447986
P2RecruitingSystemic Lupus Erythematosus (SLE)1202027-09-30
SG2918
NCT07454187
P1/2RecruitingRelapsed/Refractory Multiple Myeloma402027-09-30
SG1827
NCT07774611
P1/2RecruitingAdvanced Solid Tumors1802028-06-30